In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arbutus Biopharma (ABUS), with a price target of $10.00. The company’s shares closed last Thursday at $3.14.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 15.2% and a 41.5% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Aurinia Pharmaceuticals, and Paratek Pharmaceuticals.
Arbutus Biopharma has an analyst consensus of Moderate Buy, with a price target consensus of $6.40, which is a 79.3% upside from current levels. In a report released today, Chardan Capital also reiterated a Buy rating on the stock with a $5.00 price target.
See today’s analyst top recommended stocks >>
Based on Arbutus Biopharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.52 million and GAAP net loss of $18.76 million. In comparison, last year the company earned revenue of $3.06 million and had a GAAP net loss of $82.5 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.
